Nerve growth factor loaded macrophage-derived nanovesicles for inhibiting neuronal apoptosis after spinal cord injury. (August 2021)

• Record Type: Journal Article
• Authors: Xia, Nan; Gao, Zhanshan; Hu, Hengshuo; Li, Daoyong; Zhang, Chuanjie; Mei, Xifan; Wu, Chao
• Is Part Of: Journal of biomaterials applications. Volume 36:Number 2(2021)
• Page Start: 276
• Page End: 288
• Publication Date: 2021-08
• Subjects: Spinal cord injury -- nerve growth factor -- macrophage membrane -- nanovesicles -- neuroprotection; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1177/08853282211025912
• Languages: English
• ISSNs: 0885-3282

Abstract

Spinal cord injury (SCI) is an extremely destructive central nervous system lesion. Studies have shown that NGF can promote nerve regeneration after SCI. However, it cannot produce the desired effect due to its stability in the body and is difficulty in passing through the blood-brain barrier. In this study, we prepared nanovesicles derived from macrophage membrane encapsulating NGF (NGF-NVs) as a drug carrier for the treatment of SCI. Cell experiments showed that NGF-NVs were effectively taken up by PC12 cells and inhibited neuronal apoptosis. In vivo imaging experiments, a large quantity of NGF was delivered to the injured site with the aid of the good targeting of NVs. In animal experiments, NGF-NVs improved the survival of neurons by significantly activating the PI3K/AKT signaling pathway and had good behavioral and histological recovery effects after SCI. Therefore, NVs are a potential drug delivery vector for SCI therapy.